Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride (SKU: A3008) is a small-molecule inhibitor targeting Rho-associated protein kinases ROCK1 and ROCK2 with nanomolar potency (IC₅₀ ≈ 140 nM for ROCK1). It shows >200-fold selectivity against other kinases, disrupts Rho-mediated stress fiber formation, and is widely used to enhance stem cell survival and suppress tumor invasion in vitro and in vivo (ApexBio; Li et al., 2024). Y-27632 is highly soluble in DMSO, ethanol, and water with storage guidance for optimal stability. This article benchmarks its molecular action, experimental evidence, and workflow best practices with structured, cited facts.

Biological Rationale

Rho-associated protein kinases (ROCKs) are serine/threonine kinases that regulate actin cytoskeleton organization, cell motility, proliferation, and apoptosis. ROCK1 and ROCK2 are downstream effectors of the GTPase RhoA. Aberrant ROCK activity contributes to tumor progression, metastasis, and fibrotic diseases by promoting stress fiber assembly, cell contractility, and invasion (Li et al., 2024).

Selective inhibition of ROCK kinases enables researchers to dissect Rho/ROCK pathway functions, reduce pro-fibrotic and pro-metastatic phenotypes, and improve survival of sensitive cell populations such as human pluripotent stem cells (hPSCs). Y-27632 dihydrochloride, as a cell-permeable ROCK inhibitor, is extensively utilized for these purposes due to its high selectivity and well-characterized pharmacological profile (CY5 NHS Ester Review).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride specifically binds the catalytic domains of ROCK1 and ROCK2, inhibiting their kinase activity with an IC₅₀ of approximately 140 nM for ROCK1 and a K_i of 300 nM for ROCK2 (ApexBio). This inhibition prevents phosphorylation of downstream substrates such as myosin light chain (MLC) and LIM kinase, disrupting actin stress fiber formation and cell contractility.

By blocking ROCK signaling, Y-27632 interferes with Rho-mediated cytoskeletal organization, modulates the G1–S cell cycle transition, and impairs cytokinesis. This leads to decreased cell proliferation, altered cell morphology, and reduced migratory/invasive potential—critical endpoints in cancer and stem cell biology (America Peptides Review—this article provides updated in vivo benchmarks beyond vesicle release data).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 activity with an IC₅₀ of ~140 nM and ROCK2 with a K_i of 300 nM in biochemical assays (ApexBio).
• It exhibits over 200-fold selectivity for ROCK1/2 versus related kinases PKC, PKA, MLCK, and PAK (CY5 NHS Ester Review).
• Solubility in DMSO is ≥111.2 mg/mL; in ethanol, ≥17.57 mg/mL; in water, ≥52.9 mg/mL at room temperature (ApexBio).
• Warming to 37°C or brief sonication improves dissolution without compound degradation (ApexBio).
• In vitro, Y-27632 reduces proliferation of prostatic smooth muscle cells in a dose-dependent manner (ApexBio).
• In mouse colon cancer models, Y-27632 administration decreases tumor invasion and metastasis by modulating Rho/ROCK signaling (Li et al., 2024; see mouse xenograft data, Fig. 3).
• ROCK inhibition with Y-27632 enhances viability and expansion of hPSCs by suppressing apoptosis during single-cell dissociation (Carmofur Review—this article focuses on mechanistic stem cell data, while current content adds clinical tumor benchmarks).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely applied for:

• Dissecting the Rho/ROCK signaling pathway in cancer, neurobiology, and cardiovascular studies.
• Enhancing survival and clonogenicity of hPSCs, iPSCs, and epithelial progenitors during culture or passaging.
• Inhibiting tumor cell motility, invasion, and metastasis in preclinical cancer models.
• Modulating cytokinesis and cell cycle in cell proliferation assays.

For further reading on advanced stem cell and anti-aging strategies, see this precision workflow article—here, we update with more recent cancer invasion data and solubility best practices.

Common Pitfalls or Misconceptions

• Y-27632 is not a pan-kinase inhibitor; selectivity for ROCK1/2 >200x over PKC, PKA, MLCK, PAK is experimentally verified.
• Long-term storage of Y-27632 solutions at room temperature leads to degradation; solid should be stored desiccated at ≤4°C, solutions at <–20°C.
• Y-27632 does not directly inhibit bacterial genotoxin pathways, such as colibactin biosynthesis (Li et al., 2024).
• High concentrations (>100 μM) may cause off-target effects; optimal usage is at 1–10 μM for most stem cell and cancer assays.
• Not suitable as a therapeutic for human use; for research applications only.

Workflow Integration & Parameters

Preparation: Dissolve Y-27632 dihydrochloride in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL) at room temperature. Warm to 37°C or use a brief ultrasonic bath to aid dissolution. Filter sterilize for cell culture applications. Prepare fresh solutions or store aliquots at <–20°C for up to several months. Avoid repeated freeze-thaw cycles (ApexBio).

Dosage and Usage: For stem cell culture, 10 μM is typical. For cancer invasion assays, 1–20 μM is common. Titrate based on cell type and endpoint. Include vehicle controls to ensure specificity. Monitor for cytotoxicity at higher concentrations.

Experimental Controls: When using Y-27632, always include untreated and vehicle-treated controls. Confirm pathway modulation by assaying downstream substrate phosphorylation (e.g., MLC2) and morphological changes.

Conclusion & Outlook

Y-27632 dihydrochloride remains a gold-standard, selective ROCK1/2 inhibitor for dissecting cytoskeletal and cell signaling processes in cancer, stem cell, and regenerative biology. Its high potency, selectivity, and well-characterized solubility make it indispensable for reproducible, mechanistic studies. As research advances in Rho/ROCK pathway targeting, Y-27632 will continue to underpin translational workflows, though clinical application remains limited to preclinical models. For detailed protocols and advanced applications, consult the product page and related reviews.